Comparison of Killing Activity of Micafungin Against Six Candida Species Isolated from Peritoneal and Pleural Cavities in RPMI-1640, 10 and 30% Serum

Mycopathologia. 2018 Dec;183(6):905-912. doi: 10.1007/s11046-018-0302-5. Epub 2018 Oct 31.

Abstract

Currently echinocandins are recommended in Candida peritonitis and pleuritis. We determined micafungin killing rates (k values) at therapeutic concentrations (0.25-2 mg/L) in RPMI-1640 with and without 10 and 30% serum mimicking in vivo conditions against six Candida species isolated from peritoneal and pleural fluid. In RPMI-1640, micafungin was fungicidal against C. glabrata, C. krusei and C. kefyr within 2.27 ± 10.68, 2.69 ± 10.29 and 3.10 ± 4.41 h, respectively, while was fungistatic against C. albicans, C. tropicalis and C. parapsilosis. In 10% serum, ≥ 0.25, ≥ 0.5, ≥ 0.5 and ≥ 1 mg/L micafungin produced positive k values (killing) for all C. albicans, C. glabrata, C. kefyr and C. krusei, respectively. In 30% serum, 2 mg/L micafungin produced killing against all C. albicans, C. glabrata and C. kefyr isolates, but was ineffective against C. krusei, C. parapsilosis and 2 of 3 C. tropicalis. Micafungin exposure should be increased against non-albicans species to eradicate fungi from peritoneal and pleural cavities.

Keywords: Candida peritonitis; Candida pleuritis; Echinocandins; Non-albicans Candida species.

MeSH terms

  • Antifungal Agents / pharmacology*
  • Candida / drug effects*
  • Candida / isolation & purification
  • Candidiasis, Invasive / microbiology*
  • Humans
  • Micafungin / pharmacology*
  • Microbial Sensitivity Tests / methods*
  • Microbial Viability / drug effects
  • Peritoneal Cavity / microbiology*
  • Pleural Cavity / microbiology*

Substances

  • Antifungal Agents
  • Micafungin